
USD
+$0.00
(+0.00%
)At Close (As of Dec 15, 2025)
$1.22B
Market Cap
-
P/E Ratio
-4.4
EPS
$71.50
52 Week High
$7.76
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $8.8M |
| Total Revenue | $27M |
| Cost Of Revenue | $18M |
| Costof Goods And Services Sold | $18M |
| Operating Income | -$184M |
| Selling General And Administrative | $51M |
| Research And Development | $144M |
| Operating Expenses | $193M |
| Investment Income Net | - |
| Net Interest Income | -$42M |
| Interest Income | $21M |
| Interest Expense | $64M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $13M |
| Income Before Tax | -$237M |
| Income Tax Expense | $2.4M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$240M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$173M |
| Ebitda | -$161M |
| Net Income | -$240M |
| Field | Value (USD) |
|---|---|
| Total Assets | $557M |
| Total Current Assets | $390M |
| Cash And Cash Equivalents At Carrying Value | $159M |
| Cash And Short Term Investments | $159M |
| Inventory | $0 |
| Current Net Receivables | $5.9M |
| Total Non Current Assets | $166M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $71M |
| Intangible Assets Excluding Goodwill | $71M |
| Goodwill | $22M |
| Investments | - |
| Long Term Investments | $27M |
| Short Term Investments | $209M |
| Other Current Assets | $17M |
| Other Non Current Assets | - |
| Total Liabilities | $563M |
| Total Current Liabilities | $40M |
| Current Accounts Payable | $7.2M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $3.6M |
| Total Non Current Liabilities | $523M |
| Capital Lease Obligations | $15M |
| Long Term Debt | $51M |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $66M |
| Other Current Liabilities | $29M |
| Other Non Current Liabilities | $454M |
| Total Shareholder Equity | -$6.8M |
| Treasury Stock | - |
| Retained Earnings | -$1.1B |
| Common Stock | $2.9M |
| Common Stock Shares Outstanding | $49M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $8.8M |
| Total Revenue | $27M |
| Cost Of Revenue | $18M |
| Costof Goods And Services Sold | $18M |
| Operating Income | -$184M |
| Selling General And Administrative | $51M |
| Research And Development | $144M |
| Operating Expenses | $193M |
| Investment Income Net | - |
| Net Interest Income | -$42M |
| Interest Income | $21M |
| Interest Expense | $64M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $13M |
| Income Before Tax | -$237M |
| Income Tax Expense | $2.4M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$240M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$173M |
| Ebitda | -$161M |
| Net Income | -$240M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
uniQure NV is a pioneering gene therapy company based in Amsterdam, Netherlands, focused on delivering innovative treatments for genetic disorders and severe diseases. Leveraging its proprietary AAV-based gene therapy platform, uniQure is addressing significant unmet medical needs in critical areas, including hemophilia and neurodegenerative disorders. The company boasts a robust pipeline of promising product candidates and is committed to enhancing patient care through the advancement of breakthrough genetic therapies, positioning itself as a leader in the dynamic gene therapy market.